Forum Agenda

July 22, 13:30-17:30

Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3

Stay tuned

13:30-13:50 Cross-Border BD Transactions: Lessons Learned and Best Practices
Gerry Zhao: Partner, JunHe LLP

 

13:50-14:05 From License-out to Evidence-Ready: The Next Phase of Global Business Development for Chinese Innovative Biopharma
Erdong Cheng: Managing Director, Custom Solutions, APAC Norstella

 

14:05-14:20 Statistics-Driven Global Business Development
Zhenming Xun: Former Global Head of Biostatistics and Data Management, Daiichi Sankyo

 

14:20-14:35 Tax Considerations for Cross-Border BD Transactions and Overseas Investment in Innovative Biopharma
TBD, Ernst & Young

 

14:35-14:50 Intellectual Property Considerations for Collaborations with U.S. Pharmaceutical Companies
Yieyie Yang: Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

 

14:50-15:05 Deepen Cross-border Financial Services to Fully Support Enterprises in Overseas Business Development
Alice Song: Head of International Business Department, Bank of Jiangsu Shanghai Branch

 

15:05-16:00 Nuts, Bolts and Best Practices of Cross-Border BD and Investment Deals
Jimmy Zhang (Moderator): Executive Mentor, QB3/Bakar Labs, UC Berkeley
Albert Ren: Vice President, Head of WWBD China, Pfizer
John Zhu: Founder, Chairman and CEO of Duality Bio
Chen Ming Yu: Founder & Managing Partner, TCG Crossover
Kevin Guan: Lawyer of Goodwin’s Asia Life Sciences

Jenkins Fung: Head of North Asia ex-Japan at SS&C Intralinks

 

16:00-16:40 Panel Discussion I: Advancing Global Collaboration for Innovative Medicines: Strategy, Capabilities, and Value Creation
Han Dai (Planner & Moderator): Chief Innovation Officer, Head of Investment & Strategy, Vivarium
Dan Wang: Head of External Scientific Innovation Asia Pacific, Johnson & Johnson
Fred Li: Director, Search & Evaluation, Novartis China
Frank Luo: Associate Vice President, Simcere Zaiming (North America and Europe BD)
Yi Ding: BD Director, RA Swiftbridge
Morgan Xu: Partner, Foley Hoag LLP

 

16:40-17:30 Panel Discussion II: Reimagining the Biopharma BD Ecosystem: Multi-Stakeholder Collaboration and Emerging Paradigms
Mingde Xia (Moderator): Founder, Chairman & CEO, Innolake Biopharm
Jenny Yang: Head of External Innovation, Asia Pacific, Novo Nordisk A/S
Jian Lin: Senior Director, External Innovation, JNJ
Dong Chen: Executive Director, External Innovation, AbbVie
Betty Huang: VP and Head of Collaborate to Cure Hub China, Bayer Pharmaceuticals
Hao Huang: Head of the New Business for Marketing Solutions, LinkedIn China
Shuai Chen: Deputy General Manager, Overseas Business Department, Bank of Ningbo (NBCB)